100-Week Data vs. 52-Week Data in PANORAMA

Jennifer I. Lim, MD

Show Description +

Jennifer Lim, MD, reviews 100-week data from the PANORAMA study, which evaluated the efficacy of aflibercept in patients with nonproliferative diabetic retinopathy. Dr. Lim compares 100-week study results with 52-week study results, delving into data on improvements in disease severity and complication rates.

Posted: 5/13/2020

Keywords:

aflibercept

•

Diabetic Retinopathy

•

retina-meeting-recap

Up Next

Name: 100-Week Data vs. 52-Week Data in PANORAMA
Uploaded: 2020-05-13T14:06:00+00:00
Description: Jennifer Lim, MD, reviews 100-week data from the PANORAMA study, which evaluated the efficacy of aflibercept in patients with nonproliferative diabetic retinopathy. Dr. Lim compares 100-week study results with 52-week study results, delving into data on improvements in disease severity and complication rates.